Infectious Disease Frontier

As antimicrobial resistance (AMR) continues to be a growing global public health challenge, treating infections caused by resistant bacteria has become increasingly difficult. Recently, the Infectious Diseases Society of America (IDSA) released the "IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections," providing clinicians with valuable treatment recommendations. This document primarily addresses infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E), AmpC beta-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia, offering specific and comprehensive treatment advice. Infectious Disease Frontier has translated and summarized the relevant recommendations from the document for reference by our readers.

With continuous advancements in technology and deepening research in the field of AIDS prevention, new breakthroughs in HIV treatment and management have emerged. During the 25th International AIDS Conference, "Infectious Diseases Frontier" invited Dr. Hui Wang from Shenzhen Third People's Hospital and Dr. Huachun Zou from the Fudan University School of Public Health for an in-depth dialogue. They shared the latest research findings on the impact of integrase inhibitors (INSTIs) on patients' weight and BMI and discussed the challenges faced in HIV treatment and management. Furthermore, significant progress has been made in HIV prevention, with the clinical trial of Gilead's PrEP drug Lenacapavir—administered once every six months—showing remarkable results among South African women. This series of research findings not only advances the development of AIDS treatment but also provides new insights and directions for global AIDS prevention strategies.